TG Therapeutics, Inc.
TGTX
Helyezés a részvények között
#2401
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Részvényárfolyam
$53.19
Piaci kapitalizáció
$8.14B
Változás (1 nap)
-2.46%
Változás (1 év)
51.02%
Ország
US
Kereskedés TG Therapeutics, Inc. (TGTX)
Kategória
Healthcare
TG Therapeutics, Inc. (TGTX) nyeresége
Nyereség ekkor: Jun 2026 TTM: $101.60M
TG Therapeutics, Inc. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $101.60M. 2023 évben a vállalat $13.06M nyereséget ért el, növekedés a 2022 év nyereségéhez, amely $-223.81M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
TG Therapeutics, Inc. nyereségtörténete 2000 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $101.60M | 296.96% |
| 2024 | $25.59M | 95.94% |
| 2023 | $13.06M | -105.84% |
| 2022 | $-223.81M | -35.70% |
| 2021 | $-348.10M | 24.60% |
| 2020 | $-279.38M | 61.61% |
| 2019 | $-172.87M | -0.35% |
| 2018 | $-173.48M | 46.43% |
| 2017 | $-118.48M | 51.40% |
| 2016 | $-78.25M | 24.31% |
| 2015 | $-62.95M | 12.85% |
| 2014 | $-55.78M | 172.39% |
| 2013 | $-20.48M | -20.79% |
| 2012 | $-25.85M | 2,807.86% |
| 2011 | $-889.07K | -166.04% |
| 2010 | $1.35M | -147.54% |
| 2009 | $-2.83M | -39.27% |
| 2008 | $-4.66M | -61.25% |
| 2007 | $-12.03M | 20.31% |
| 2006 | $-10.00M | -48.32% |
| 2005 | $-19.35M | 218.71% |
| 2004 | $-6.07M | -15.91% |
| 2003 | $-7.22M | 363.40% |
| 2002 | $-1.56M | -12.31% |
| 2001 | $-1.78M | -69.86% |
| 2000 | $-5.90M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $5.27B | 5,091.88% |
US
|
|
| $-3.09B | -3,138.42% |
US
|
|
| $-4.02B | -4,052.99% |
AU
|
|
| $1.95B | 1,819.95% |
NL
|
|
| - | - |
CH
|
